7-Nov-2024 3:05 PM CST - Business Wire Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter 2024, ending September 30, 2024. "Lantern is achieving remarkable momentum, balancing meticulous execution with innovation. While progressing on
31-Oct-2024 7:00 AM CST - Business Wire Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2024 operating and financial results webcast on Thursday, November 7, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial
23-Oct-2024 7:45 AM CST - Business Wire Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Wednesday, October 30, 2024, at 10:30 a.m. ET at the Mandarin Oriental in New York, NY. Webcast Link: https://www.meetmax.com/sched/event_106721/conference_register.html Confe
21-Oct-2024 7:00 AM CST - Business Wire Lantern Pharma to Host & Participate in Two Public Webinars During October Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that they will be participating in and hosting two webinars that are open to the public during October. Lantern expects to discuss in detail how big data and AI are being leveraged to advance the development of multiple indications for drug-candidates
7-Nov-2024 3:05 PM CST - Business Wire Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter 2024, ending September 30, 2024. "Lantern is achieving remarkable momentum, balancing meticulous execution with innovation. While progressing on
31-Oct-2024 7:00 AM CST - Business Wire Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2024 operating and financial results webcast on Thursday, November 7, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial
23-Oct-2024 7:45 AM CST - Business Wire Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Wednesday, October 30, 2024, at 10:30 a.m. ET at the Mandarin Oriental in New York, NY. Webcast Link: https://www.meetmax.com/sched/event_106721/conference_register.html Confe
21-Oct-2024 7:00 AM CST - Business Wire Lantern Pharma to Host & Participate in Two Public Webinars During October Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that they will be participating in and hosting two webinars that are open to the public during October. Lantern expects to discuss in detail how big data and AI are being leveraged to advance the development of multiple indications for drug-candidates